Regado Biosciences Inc 4
4 · Regado Biosciences Inc · Filed Aug 29, 2013
Insider Transaction Report
Form 4
QUAKER BIO VENTURES LP
10% Owner
Transactions
- Purchase
Common Stock, par value $0.001 per share
2013-08-27$4.00/sh+71,810$287,240→ 1,294,021 total - Conversion
Series E Preferred Stock
2013-08-27−807,652→ 0 total→ Common Stock, par value $0.001 per share (48,362 underlying) - Conversion
Series C Preferred Stock
2013-08-27−4,566,908→ 0 total→ Common Stock, par value $0.001 per share (273,468 underlying) - Conversion
Common Stock, par value $0.001 per share
2013-08-27+399,201→ 435,129 total - Conversion
Common Stock, par value $0.001 per share
2013-08-27+273,468→ 708,597 total - Conversion
Common Stock, par value $0.001 per share
2013-08-27+465,252→ 1,173,849 total - Conversion
Common Stock, par value $0.001 per share
2013-08-27+48,362→ 1,222,211 total - Conversion
Series B Preferred Stock
2013-08-27−6,666,667→ 0 total→ Common Stock, par value $0.001 per share (399,201 underlying) - Conversion
Series D Preferred Stock
2013-08-27−7,769,715→ 0 total→ Common Stock, par value $0.001 per share (465,252 underlying)
Footnotes (5)
- [F1]The reportable securities are directly held by Quaker BioVentures, L.P. (the "Reporting Person"). Quaker BioVentures Capital, L.P. ("Quaker Capital LP") is the general partner of the Quaker. Quaker BioVentures Capital, LLC ("Quaker Capital LLC") is the general partner of Quaker Capital LP and has voting and dispositive power over the shares held by the Reporting Person. Voting and investment determinations made by Quaker Capital LLC with respect to the shares held by the Reporting Person are made by an investment committee of Quaker Partners Management, L.P., which committee includes P. Sherrill Neff, a member of the board of the directors of the Company.
- [F2]The shares of Series B Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series B Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
- [F3]The shares of Series C Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
- [F4]The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
- [F5]The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.